iCo Therapeutics Announces AGM Voting Results
Vancouver, British Columbia--(Newsfile Corp. - June 28, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the results of voting at its 2019 Annual General Meeting of Shareholders held on June 27, 2019.A total of 20,801,184 common shares were voted in connection with the meeting, representing approximately 19% of the issued and outstanding common shares of the company. Shareholders voted as follows:MotionVoted For
2019-06-28 8:00 AM EDT
iCo Therapeutics Announces First Quarter 2019 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the Quarter ended March 31, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "during the first quarter we were able to close a financing with several healthcare...
2019-05-30 4:39 PM EDT
iCo Therapeutics Announces 2018 Year End Financial Results
Vancouver, British Columbia--(Newsfile Corp. - April 30, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "2018 represented a year of significant advances as we entered into a clinical trial...
2019-04-30 6:37 PM EDT
iCo Therapeutics Inc. Announces the Issuance of 3,600,000 Units Pursuant to its Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - March 5, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a further 3,600,000 units ("Units") pursuant to its previously announced non-brokered private placement (the "Private Placement"). The Units were sold at a price of $0.05 per Unit, for total gross proceeds to the Company of C$180,000 (the "Fourth Tranche"), bringing the total number of Units and gross proceeds under...
2019-03-05 7:25 AM EST
iCo Therapeutics Inc. Announces the Issuance of 14,400,000 Units Pursuant to its C$1,250,000 Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - February 25, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a total of 14,400,000 units (the "Units") pursuant to its previously announced non-brokered private placement (the "Private Placement"). The Units were sold at a price of $0.05 per Unit, for total gross proceeds to the Company of C$720,000.Each Unit issued pursuant to the Private Placement consists of one common...
2019-02-25 8:00 AM EST
iCo Therapeutics Inc. Announces Upsizing of Non-Brokered Private Placement to $1,250,000 CDN
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announces an upsizing of a previously announced Non-brokered private placement to $1,250,000 CDN.Each Unit issued pursuant to the Private Placement consists of one common share in the capital of the Company (a "Common Share") and one common share purchase warrant (a "Warrant") exercisable at $0.075 for 36 months from the date of the closing of the...
2019-02-19 6:00 AM EST
iCo Therapeutics Inc. Announces Notice of Termination of Sub License for Bertilimumab (iCo-008)
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announces that on Friday February 15, 2019 the Company delivered written notice terminating, with immediate effect, its product sublicense agreement with Immune Pharmaceuticals (IMNP: OTCQB), related to iCo-008 (Bertilimumab). Subsequent to the above noted termination, Immune Pharmaceuticals filed a voluntary petition for bankruptcy in the District of...
2019-02-19 5:45 AM EST
iCo Therapeutics Inc. Announces the Issuance of 4,000,000 Units Pursuant to its C$750,000 Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - February 11, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a total of 4,000,000 units (the "Units") to a Canadian institutional investor pursuant to its previously announced non-brokered private placement (the "Private Placement"). The Units were sold at a price of $0.05 per Unit, for total gross proceeds to the Company of C$200,000. Each Unit issued pursuant to the...
2019-02-11 7:19 PM EST
iCo Therapeutics Inc. Announces Non-Brokered Private Placement to Raise C$750,000
Vancouver, British Columbia--(Newsfile Corp. - January 31, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQX: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a total of 3,000,000 units (the "Units") pursuant to the first tranche of a non-brokered private placement (the "Private Placement"). The Company plans to issue up to 15,000,000 Units at a price of $0.05 per Unit for total gross proceeds of $750,000 pursuant to the Private Placement. Each Unit...
2019-01-31 8:06 PM EST
iCo Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - November 29, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter and nine months ended September 30, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "This quarter was a period of significant achievement for iCo...
2018-11-29 5:00 PM EST
iCo Therapeutics Provides Corporate Update, Including Drug Supply for Next Oral Amphotericin B Efficacy Study
Vancouver, British Columbia--(Newsfile Corp. - November 15, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced several positive corporate developments and updated guidance on milestones for two drug candidates.-iCo Therapeutics announces that it now has sufficient drug supply for a proposed mid-staged clinical trial, which may be as large as 90 patients in size, investigating the efficacy and safety study of its oral Amphotericin B (oral Amp B)...
2018-11-15 8:00 AM EST
iCo Therapeutics Announces Oral Amphotericin B Clinical Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - October 23, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced the formation of an oral Amphotericin B clinical advisory board with the appointment of Dr. John Perfect and Dr. David Denning.Stated Dr. Peter Hnik, Chief Medical Officer, "we look forward to working with our clinical advisors as we refine the design of mid staged clinical studies for our oral Amphotericin B candidate. We are fortunate to...
2018-10-23 8:00 AM EDT
iCo Therapeutics Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - October 2, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced several positive corporate developments and updated guidance on milestones for two drug candidates.iCo Therapeutics Australia Pty Ltd. has received full payment of approximately $462,000 Australian dollars (AUD) for R&D expenditures conducted during its past fiscal year, during which the Company conducted a Phase 1 clinical study. Refundable...
2018-10-02 8:00 AM EDT
iCo Therapeutics Announces Additional Positive Pharmacokinetic Results and Presentation at Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - September 6, 2018) - iCo Therapeutics ("iCo" or the "Company") (TSXV: ICO) (OTCQB: ICOTF), today announced additional positive pharmacokinetic data from its recent Phase 1 study of its Oral Amphotericin B (Oral Amp B) candidate. Previously the Company reported that Oral Amp B achieved a median Cmax of 28 ng/mL and AUC0-inf of 1030 hr*ng/mL at the lowest dose of Oral Amphotericin B of 100 mg, demonstrating superiority of area under the...
2018-09-06 8:00 AM EDT
iCo Therapeutics Announces Second Quarter 2018 Financial Results And Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - August 29, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter and six months ended June 30, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "the quarter represented a period of significant achievement for iCo...
2018-08-29 6:32 PM EDT
iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials - Phase 1 Oral Amphotericin B
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced a positive pharmacokinetic secondary end point in its Phase 1 clinical study. Previously the Company reported that the study met its primary endpoint of safety and tolerability of iCo-019 (Oral Amp B) following oral administration of single ascending doses (4 dose levels) in healthy...
2018-07-16 8:00 AM EDT
iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced a positive primary end point in its Phase 1 clinical study. The study met its primary endpoint of safety and tolerability of iCo-019 (Oral Amp B) following oral administration of single ascending doses (4 dose levels) in healthy subjects. There were no serious adverse events (SAEs) and...
2018-06-27 8:00 AM EDT
iCo Therapeutics Provides Corporate Update, Announces Completion of Phase 1 Recruitment
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the completion of recruitment of all 32 subjects in the Company's Phase 1 Oral Amphotericin B (Oral Amp B) study. Phase 1 Oral Amp B Clinical TrialThe Phase 1 Australian study is a randomized, double-masked, placebo-controlled, single dose ascending study to assess the safety, tolerability, and bioavailability of iCo-019 (Oral Amphotericin B)....
2018-06-20 8:00 AM EDT
iCo Therapeutics Announces First Quarter 2018 Financial Results And Update On Phase 1 Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the quarter ended March 31, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS")."Recently, we dosed our first subject with our novel Oral Amphotericin B (Oral AmpB) formulation. Strong recruitment has resulted in our dosing of...
2018-05-30 4:18 PM EDT
iCo Therapeutics Announces Year End 2017 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the year ended December 31, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").2017 Financial & Operational HighlightsDuring the year, we advanced our oral formulation of Amphotericin B completing our 14-day GLP toxicology...
2018-04-24 8:47 PM EDT